Process Safety Scientist
About the job
- Bachelor’s degree in chemistry or chemical engineering
- Ability to work in highly collaborative, cross-functional environment involving global customers, labs, and manufacturing sites
- Understanding of chemical principles, good lab skills, neat working habits and excellent oral and written communication
- Good time management and organizational skills for supporting multiple projects
- Ability to obtain New Jersey Grade H permit to use explosives and to pass NJ State Police and ATF background checks
- Authorization to work in the United States
- Mechanical skills to work with common tools and small diameter tubing and tube fittings
- Ability to lift and move safely equipment and materials weighing up to 40 pounds
- Work closely with process and plant engineers and quality and regulatory personnel to generate material and process hazard data, enabling Ashland and external customers to handle materials in manufacturing operations in a safe, sustainable and compliant manner.
- Maintain and calibrate lab equipment and instrumentation. Diagnose and repair faulty instrumentation, as needed.
- Keep detailed records of experiments, interpret test data and write test reports.
- Follow all safety policies and procedures, performing all duties in a safe manner.
- With supervisor, design and perform non-routine experiments to obtain calorimetric and manometric process safety data related to run-away reactions.
- With experience, the candidate will develop an understanding of testing methodologies, enabling design of custom testing protocols, and will obtain the problem-solving skills to identify causal factors for anomalies in test data.
- Process and evaluate test requests and incoming chemicals and samples, performing sample preparation and pre-test safety reviews.
- Maintain inventories of chemicals and spare parts. Ensure timely disposal of waste to keep work area clean and organized.
- Maintain detailed inventory of igniters and generate monthly NJ explosives use report
- 2 to 5 years of work experience in process safety testing, analytical testing or quality control
- Knowledge of electrical principles and pressure and temperature measurement
- Experience working with compressed gases
- Experience in particle size analysis, moisture analysis, particle size reduction (milling and sieving), adiabatic calorimetry and Dust Hazard Characterization testing (20L sphere, MIE, MAIT, LIT, etc.)
- Knowledge of ASTM and EU combustible dust testing standards
- Knowledge of UN Tests for flammable solids, self-heating solids and oxidizing solids
- Understanding of synthetic and mechanistic organic chemistry
About the company
Ashland is a diversified specialty chemicals company that originated as an oil refinery in 1924 and gradually shifted into chemicals, construction, and coal before fully reinventing itself as a pure-play specialty chemicals provider. Its products serve the personal care, pharmaceutical, and coatings markets. The company operates by developing and supplying chemical ingredients used in formulations across these industries, rather than delivering consumer finished goods. Compared with competitors, Ashland focuses on specialty chemical ingredients with an emphasis on performance materials and advanced additives, supported by a history of strategic acquisitions and spin-offs that steered it away from refining into differentiated chemical solutions. The company’s goal is to grow as a leading supplier of high-value, specialty ingredients by applying chemistry to improve the performance and quality of its customers’ products.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Covington, Kentucky
Founded
1924
Get referred to Ashland
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 29, 2026 Q3 sales rose 7% to $497 million.
- Ashland generated $103 million ongoing free cash flow and cut inventory nearly $80 million.
- Sept. 17 Innovation Day showcased new commercial opportunities across technology platforms.
What critics are saying
- Ancora's July 2026 settlement keeps capital-allocation pressure alive through 2028.
- Specialty Additives and Intermediates posted EBITDA declines in Q3 2026.
- A failed sale process leaves Ashland exposed to activist breakup demands.
What makes Ashland unique
- Ashland's oral biologics excipients, including Permexa sodium caprate, target GLP-1 formulations.
- Sept. 22, 2026 agrimer eco-disperse OD uses transformed vegetable oils and biodegradability.
- Its portfolio spans Life Sciences, Personal Care, Specialty Additives, and Intermediates.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Paid Holidays
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Wellness Program
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Ashland launches Forzango condurango bark extract for skin health. The cosmeceutical ingredient is formulated to support the skin's detoxification process, antimicrobial activity, and barrier function. October 8, 2026 Associate Editor, Nutraceuticals World Ashland Inc. announced the launch of Forzango Biofunctional, an active ingredient obtained by supercritical CO2 extraction from traceable, ethically-sourced, and abundant condurango bark, to support skin health. The ingredient addresses concerns about the impact that sweat, physical stress, and sun exposure can have on skin health. "The old assumption was that active living came at your skin's expense. The new one is that they're on the same side," said Eloïse Dewitte, global marketing lead for biofunctionals. "Our customers are formulating for people who train, commute, travel and go out, often on the same day. What they need isn't skin repair after the fact, it's skin with endurance." According to Ashland, the ingredient supports the skin's detoxification process; increases mitochondrial complex IV production in the skin; strengthens skin barrier function/microbial defense; and increases biological signals related to skin comfort. Clinical results were obtained on a mixed panel of 30 men and women, against placebo - a deliberately unisex protocol for a deliberately unisex claim. After six weeks, fine lines, roughness and signs of oxygenation significantly improved, 80 percent of volunteers agreed their skin felt more comfortable and 60 percent found it looked smoother. Forzango biofunctional is obtained by supercritical CO2 extraction from condurango bark (Marsdenia condurango), a vigorous liana that climbs Andean trees to reach the light and thrives at 1,400 to 2,100 meters, adapting to low oxygen levels. Its name comes from condur-angu, "eagle remedy." The ingredient is the result of a ten-year sourcing program implemented by a trusted partner of Ashland in Colombia and the first foreign initiative to obtain a bioprospection research permit in the country. Traditionally wild-harvested, condurango was domesticated through a dedicated cultivation project in the Valle del Cauca, with seeds and nurseries certified by the Instituto Colombiano Agropecuario. Ten smallholder farmers now grow it under multi-year contracts with technical training, organic-farming practices and fair pricing, under an ABS-compliant benefit-sharing agreement aligned with the 12 criteria of negocios verdes. "Relieving pressure on a wild resource while creating real economic value for local growers was the only acceptable way to build this supply chain," said Frédéric Faugeroux, general manager of biofunctionals. "It's traceable, ethical and abundant." Forzango is oil-soluble, preservative-free and recommended at one percent use level. The ingredient is 100% natural origin (ISO 16128), COSMOS-approved, readily biodegradable (OECD 301D), vegan, non-GMO, and China-compliant (IECIC listed). Ashland recommends use across active consumer products including pre-workout face primers and sport SPF sticks, cooling recovery mists and gel-creams, anti-friction body balms, and daily endurance serums, barrier creams and post-shave care. Add us as a preferred source on Google. Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.
Ashland Inc. launches agrimer? Eco-Disperse OD TVO? Polymeric dispersant. Published on 09/22/2026 at 11:45 am EDT S&P Capital IQ Ashland Inc. announced the global launch of agrimer? eco-disperse OD TVO? polymeric dispersant, a patented, nature-based dispersant developed for non-aqueous crop protection formulations. The introduction represents the latest commercial innovation from the TVO? platform. Agrimer? eco-disperse OD was engineered so agrochemical formulators could address the growing industry challenge of delivering high-performance formulations while advancing sustainability goals and meeting increasingly complex regulatory expectations. The new polymeric dispersant enables effective stabilization and uniform dispersion of water-insoluble active ingredients, helping improve formulation performance, stability and application efficiency. The technology offers nature-based, inherently biodegradable and microplastic-free attributes that support the transition toward more environmentally responsible crop protection products. Derived from transformed vegetable oil, agrimer? eco-disperse OD helps improve dispersion stability, enhance leaf adhesion, coverage and rain fastness. The technology reduces common formulation challenges such as active ingredient settling and nozzle clogging, helping customers improve product consistency and field performance. Its broad formulation compatibility, ease of use and competitive cost-in-use profile provide additional flexibility for formulators developing suspension concentrates and other non-aqueous formulations. (C) S&P Capital IQ - GlobeNewswire - 2026
Evonik snaps up Justine Cotton to head global brand partnerships. * September 04, 2026 Justine Cotton has joined Evonik from Ashland to be the German personal care ingredient maker's global brand partner and claims manager. France-based Cotton was with Ashland for the past 16 years, most recently as global marketing manager for biofunctionals. She joins Evonik's Actives Consumer Excellence unit, a global team of experts fostering collaboration and excellence. "I'm thrilled to bring my passion and expertise in longevity science and cosmetic actives to the Actives Consumer Excellence unit, and to embark on this new chapter with such an inspiring team," said Cotton. "What has already impressed me is the incredible combination of science, innovation, technologies and, above all, talented and knowledgeable people I'll have the opportunity to work with," she added. "I can already feel there is so much to learn, create and achieve together."
Ashland to host Innovation Day for analysts and investors. August 31, 2026 18:30 ET | Source: Ashland, Inc. Wilmington, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) - Ashland Inc. (NYSE: ASH) will host a live Innovation Day webcast for analysts and investors from Wilmington, Delaware on September 17, 2026. The event will provide an updated view of Ashland's Technology Platforms, including their commercial progress and scalability. Registration is required and can be accessed from the following link: innovationday26.ashland.com Participants will hear from Ashland executives and senior technology leaders as they provide an in-depth review of the latest innovations and expanding commercial opportunities. The presentations will detail how these advancements are poised to impact key markets and drive organic growth. Following formal remarks, participants will have the opportunity to engage directly in a moderated question and answer (Q&A) session. Ashland leaders presenting at the event include: * Guillermo Novo, chair, and chief executive officer * Osama Musa, senior vice president and chief technology officer * Jim Minicucci, senior vice president and general manager, personal care * Alessandra Faccin, senior vice president and general manager, life sciences and intermediates * Dago Caceres, senior vice president and general manager, specialty additives * William Whitaker, senior vice president and chief financial officer * Sandy Klugman, director, investor relations Presentations will begin promptly at 9:00 a.m. ET and conclude after the Q&A session at approximately 11:00 a.m. ET. Registration information and further event details can be found on Ashland's investor website at http://investor.ashland.com A webcast of the event will be available live and can be accessed, along with supporting materials, through the Ashland website. A replay will be available within 24 hours of the live event and will be archived, along with supporting materials, on the Ashland website for 12 months. Copies of the presentation may also be requested by sending an email to [email protected] About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers - from renowned scientists and research chemists to talented engineers and plant operators - thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. (TM) Trademark, Ashland or its subsidiaries, registered in various countries. FOR FURTHER INFORMATION: | Investor Relations: | Media Relations: | | Sandy Klugman | Carolmarie C. Brown | | +1 (302) 594-7777 | +1 (302) 995-3158 | | [email protected] | [email protected] | Attachments
Ashland has launched permexa sodium caprate, an intestinal permeation enhancer designed to support the development and commercialisation of oral peptide and biologic drug products, including GLP-1 agonists. The excipient addresses key challenges in oral drug delivery by combining permeability enhancement with improved manufacturing properties such as powder flow and compressibility. The launch responds to growing pharmaceutical investment in oral alternatives to injectable therapies, driven by patient convenience and treatment adherence benefits. Prior to the commercial launch, Ashland recorded engagement with multiple pharmaceutical, biotech, and contract development organisations globally through sampling activities and formulation development discussions. Ashland plans further expansion of its oral biologics portfolio. The company has additional products in development and intends to leverage synergies with its existing vinyl pyrrolidone and derivatives portfolio to strengthen its position in the oral biologics delivery market.